Annual report pursuant to Section 13 and 15(d)

Document and Entity Information

Document and Entity Information - USD ($)
12 Months Ended
Dec. 31, 2019
Apr. 17, 2020
Jun. 30, 2019
Cover [Abstract]      
Entity Registrant Name INTERPACE BIOSCIENCES, INC.    
Entity Central Index Key 0001054102    
Document Type 10-K/A    
Document Period End Date Dec. 31, 2019    
Amendment Flag true    
Amendment Description This Amendment No. 2 on Form 10-K/A (this Amendment) amends the Company's Annual Report on Form 10-K for the year ended December 31, 2019, as amended, (the "Original Filing") and is being filed to show the impact of intangible asset amortization and impairment expense for its Barrett's and Thyroid assets beginning in 2014. Subsequent to the issuance of its consolidated financial statements for the year ended December 31, 2019 and the quarters ended March 31, 2020 and June 30, 2020, the Company determined that amortization should have commenced upon acquisition of those assets as opposed to the Company's previously disclosed policy of beginning asset amortization when the product was launched and generating revenue. The cumulative effect of the additional amortization expense for the periods from August 2014 to December 2019 was an increase to accumulated deficit of approximately $6.0 million to the December 31, 2019 consolidated balance sheet. This Amendment also reflects the impact of an asset impairment charge of its Barrett's asset in the fourth quarter of 2016 of approximately $11.6 million. It has been determined that an impairment charge should have been taken of the Barrett's asset in accordance with the requirements of Accounting Standards Codification (ASC) 360 as of December 31, 2016. A description of these adjustments and a summary showing their effect on the restated consolidated statements of operations for the years 2014- 2017 is provided in Note 1 to the consolidated financial statements. In addition to the errors described above, the restated financial statements also include adjustments to correct certain other immaterial errors, including previously unrecorded immaterial adjustments identified in audits of prior years' financial statements. As a result of the restatement, it was determined that the Company's disclosure controls and procedures were not effective as of December 31, 2019, as referenced in Item 9A. The Company is filing this report in order to amend certain information in Item 1A of Part I, Items 7 and 9A of Part II and Item 15 of Part IV; to reflect the restatement of the 2019 consolidated statements of operations and the notes to the consolidated financial statements attached hereto solely to the extent necessary to reflect the adjustments described herein; and to provide the principal executive officer and principal financial officer certifications pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act of 2002. Except for the foregoing items, no other information in the Original Filing is revised by this Amendment.    
Current Fiscal Year End Date --12-31    
Entity a Well-known Seasoned Issuer No    
Entity a Voluntary Filer No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business Flag true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 27,821,137
Entity Common Stock, Shares Outstanding   4,043,673  
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2019